Pharmaceutical company
Appears in 2 stories
European commercialization partner for obicetrapib
The European Commission approved two obicetrapib-based cholesterol drugs on September 21, 2026. It's the first time any CETP inhibitor has reached the market, after Pfizer, Roche, Eli Lilly and Merck spent billions on the drug class and failed.
Updated Sep 21
Elzonris sponsor; presenting new tagraxofusp combination data at ASCO 2026
The FDA approved AbbVie's Decnupaz on May 27 for blastic plasmacytoid dendritic cell neoplasm, an aggressive blood cancer. It strikes an estimated few hundred Americans a year. It's the second drug ever approved for the disease and the first doctors can start in an outpatient clinic.
Updated May 28
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
